Lipid-lowering therapy with monoclonal antibodies to proprotein convertase subtilisin-kexin type 9: Lessons from recent clinical trials

Hideki Ishii; Toyoaki Murohara

doi:10.1253/circj.CJ-17-0511

Lipid-lowering therapy with monoclonal antibodies to proprotein convertase subtilisin-kexin type 9: Lessons from recent clinical trials

Hideki Ishii
, Toyoaki Murohara

医学部・内科学（第２）

研究成果: ジャーナルへの寄稿 › 編集 › 査読

2 被引用数 (Scopus)

本文言語	英語
ページ（範囲）	1386-1387
ページ数	2
ジャーナル	Circulation Journal
巻	81
号	10
DOI	https://doi.org/10.1253/circj.CJ-17-0511
出版ステータス	出版済み - 2017

All Science Journal Classification (ASJC) codes

循環器および心血管医学

文献へのアクセス

10.1253/circj.CJ-17-0511

他のファイルとリンク

引用スタイル

@article{7bb7aad709bd474ba6ddc6ec115b4fe5,

title = "Lipid-lowering therapy with monoclonal antibodies to proprotein convertase subtilisin-kexin type 9: Lessons from recent clinical trials",

author = "Hideki Ishii and Toyoaki Murohara",

note = "Funding Information: H.I. received lecture fees from Astellas Pharma Inc., Astrazeneca Inc., Daiichi-Sankyo Pharma Inc., and MSD K. K. Toyoaki Murohara received lecture fees from Bayel Pharmaceutical Co., Ltd., Daiichi-Sankyo Co., Ltd., Dainippon Sumitomo Pharma Co., Ltd., Kowa Co., Ltd., MSD K. K., Mitsubishi Tanabe Pharma Co., Nippon Boehringer Ingelheim Co., Ltd., Novartis Pharma K. K., Pfizer Japan Inc., Sanofi-aventis K. K., and Takeda Pharmaceutical Co., Ltd. T.M. received unrestricted research grant for Department of Cardiology, Nagoya University Graduate School of Medicine from Astellas Pharma Inc., Daiichi-Sankyo Co., Ltd., Dainippon Sumitomo Pharma Co., Ltd., Kowa Co., Ltd., MSD K. K., Mitsubishi Tanabe Pharma Co., Nippon Boehringer Ingelheim Co., Ltd., Novartis Pharma K. K., Otsuka Pharma Ltd., Pfizer Japan Inc., Sanofi-aventis K. K., Takeda Pharmaceutical Co., Ltd., and Teijin Pharma Ltd.",

year = "2017",

doi = "10.1253/circj.CJ-17-0511",

language = "English",

volume = "81",

pages = "1386--1387",

journal = "Circulation Journal",

issn = "1346-9843",

publisher = "Japanese Circulation Society",

number = "10",

}

TY - JOUR

T1 - Lipid-lowering therapy with monoclonal antibodies to proprotein convertase subtilisin-kexin type 9

T2 - Lessons from recent clinical trials

AU - Ishii, Hideki

AU - Murohara, Toyoaki

N1 - Funding Information: H.I. received lecture fees from Astellas Pharma Inc., Astrazeneca Inc., Daiichi-Sankyo Pharma Inc., and MSD K. K. Toyoaki Murohara received lecture fees from Bayel Pharmaceutical Co., Ltd., Daiichi-Sankyo Co., Ltd., Dainippon Sumitomo Pharma Co., Ltd., Kowa Co., Ltd., MSD K. K., Mitsubishi Tanabe Pharma Co., Nippon Boehringer Ingelheim Co., Ltd., Novartis Pharma K. K., Pfizer Japan Inc., Sanofi-aventis K. K., and Takeda Pharmaceutical Co., Ltd. T.M. received unrestricted research grant for Department of Cardiology, Nagoya University Graduate School of Medicine from Astellas Pharma Inc., Daiichi-Sankyo Co., Ltd., Dainippon Sumitomo Pharma Co., Ltd., Kowa Co., Ltd., MSD K. K., Mitsubishi Tanabe Pharma Co., Nippon Boehringer Ingelheim Co., Ltd., Novartis Pharma K. K., Otsuka Pharma Ltd., Pfizer Japan Inc., Sanofi-aventis K. K., Takeda Pharmaceutical Co., Ltd., and Teijin Pharma Ltd.

PY - 2017

Y1 - 2017

UR - https://www.scopus.com/pages/publications/85030085066

UR - https://www.scopus.com/pages/publications/85030085066#tab=citedBy

U2 - 10.1253/circj.CJ-17-0511

DO - 10.1253/circj.CJ-17-0511

M3 - Editorial

C2 - 28579602

AN - SCOPUS:85030085066

SN - 1346-9843

VL - 81

SP - 1386

EP - 1387

JO - Circulation Journal

JF - Circulation Journal

IS - 10

ER -